What accounts for the higher clinical efficacy of intracoronary abciximab?

International Journal of Cardiology

Volumn 168, Issue 4, 2013, Pages 4410-

  De Rosa, Salvatore ^b   Caiazzo, Gianluca ^b   Torella, Daniele ^b   Indolfi, Ciro ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b NONE

Author keywords

Abciximab; Acute coronary syndrome; Intracoronary

Indexed keywords

ABCIXIMAB; CD40 LIGAND; FIBRINOGEN RECEPTOR; VITRONECTIN RECEPTOR; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; HEART MUSCLE PERFUSION; HUMAN; INFLAMMATORY CELL; LETTER; MICROCIRCULATION; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; MORTALITY;

ACUTE CORONARY SYNDROME; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION INHIBITORS;

EID: 84886293004     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.05.033     Document Type: Article

References (10)

1. A. Dominguez-Rodriguez, P. Avanzas, and P. Abreu-Gonzalez Intracoronary abciximab and local anti-inflammatory effects Int J Cardiol 168 3 2013 2872
2. S. De Rosa, G. Caiazzo, and D. Torella Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: a meta-analysis of clinical trials Int J Cardiol 168 2 2013 1298 1305
3. S. Desch, A. Siegemund, and U. Scholz Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST elevation myocardial infarction Clin Res Cardiol 101 2012 117 124
4. A. Dominguez-Rodriguez, P. Abreu-Gonzalez, and P. Avanzas Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention - effects on soluble CD40 ligand concentrations Atherosclerosis 206 2009 523 527
5. G. Sardella, G.M. Sangiorgi, and M. Mancone A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale J Cardiovasc Med (Hagerstown) 11 7 Jul 2010 529 535
6. R.S. Larson, and T.A. Springer Structure and function of leukocyte integrins Immunol Rev 114 Apr 1990 181 217
7. J.C. Reverter, S. Béguin, H. Kessels, R. Kumar, H.C. Hemker, and B.S. Coller Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis" J Clin Invest 98 3 Aug 1 1996 863 874
8. P. Golino, L. Forte, and S. De Rosa Inhibition of the tissue factor coagulation pathway Curr Vasc Pharmacol 2 4 Oct 2004 319 327
9. M. Marzilli, G. Sambuceti, R. Testa, and S. Fedele Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina J Am Coll Cardiol 40 12 Dec 18 2002 2102 2109
10. E. Romagnoli, F. Burzotta, C. Trani, G.G. Biondi-Zoccai, F. Giannico, and F. Crea Rationale for intracoronary administration of abciximab J Thromb Thrombolysis 23 1 Feb 2007 57 63